The National Ethics Committee in Biomedical Research under the Ministry of Health (MoH) approves the clinical trial results of the phase 3 of Nanocovax.

Data for protective efficacy of Nanocovax vaccine are not available

Nanocovax vaccine has met the short-term safety requirement based on the reporting result of the phase 3 mid-term clinical trial. The evaluation of efficacy was carried out among 11,430 volunteers within seven days after receiving the first shot and 5,785 people within seven days after getting the second dose, announced the Ministry of Health on September 19.